Molecular mechanisms of natural killer cell activation, J Innate Immun, vol.3, pp.216-242, 2011. ,
Human NK cell receptors/markers: a tool to analyze NK cell development, subsets and function, Cytom A, vol.83, pp.702-715, 2013. ,
High-resolution phenotyping identifies NK cell subsets that distinguish healthy children from adults, PloS One, vol.12, p.181134, 2017. ,
Human NK Cell Diversity in Viral Infection: Ramifications of Ramification, Front Immunol, vol.7, p.66, 2016. ,
Expansion Of Allogeneic NK Cells With Efficient Antibody-Dependent, Cell Cytotoxicity Against Multiple Tumor Cells. Theranostic, vol.8, pp.3856-3869, 2018. ,
Immunological and Translational Aspects of NK Cell-Based Antitumor Immunotherapies, Front Immunol, vol.7, p.492, 2016. ,
Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy, Clin Cancer Res Off J Am Assoc Cancer Res, vol.19, pp.2132-2143, 2013. ,
Different dynamics of CD4+ and CD8+ T cell responses during and after acute lymphocytic choriomeningitis virus infection, J Immunol Baltim Md, vol.1950, pp.3928-3935, 2003. ,
,
PKC-theta) in Natural Killer Cell Function and Anti-Tumor Immunity, Front Immunol, vol.3, p.187, 2012. ,
Umbilical Cord Blood Natural Killer Cells, Their Characteristics, and Potential Clinical Applications, Front Immunol, vol.8, p.329, 2017. ,
Two-Stage Priming of Allogeneic Natural Killer Cells for the Treatment of Patients with Acute Myeloid Leukemia: A Phase I Trial, PLoS One, vol.10, p.123416, 2015. ,
All-trans retinoic acid (ATRA) induces miR-23a expression, decreases CTSC expression and granzyme B activity leading to impaired NK cell cytotoxicity, Int J Biochem Cell Biol, vol.178, pp.42-52, 2014. ,
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission, Blood, vol.120, pp.4317-4340, 2012. ,
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells, Cell, vol.175, pp.1731-1743, 2018. ,
Overcome the Impairment of NK Cells for Icon and Antibody Immunotherapy of Cancer, J Immune Based Ther Vaccines Antimicrob, vol.2, pp.1-8, 2013. ,
Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma, Clin Cancer Res, vol.22, pp.5211-5222, 2016. ,
Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression, Oncotarget, vol.8, pp.24031-24044, 2017. ,
NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment, Oncoimmunology, vol.7, p.1409322, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01780378
Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds, Blood, vol.126, pp.50-60, 2015. ,
Identification of anti tumor cells carrying natural killer (NK) cell antigens in patients with hematological cancers, EBioMedicine, vol.2, pp.1364-1376, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-01867114
CD45 Isoform Profile Identifies Natural Killer (NK) Subsets with Differential Activity, PLoS One, vol.11, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01867110
Chemical metabolic inhibitors for the treatment of blood-borne cancers, Anticancer Agents Med Chem, vol.14, pp.223-255, 2014. ,
URL : https://hal.archives-ouvertes.fr/inserm-01867009
From tumor cell metabolism to tumor immune escape, Int J Biochem Cell Biol, vol.45, pp.106-119, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-00726717
Natural Killer Cells Modulation in Hematological Malignancies, Front Immunol, vol.4, p.459, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-01455668
Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience, Transfusion, vol.47, pp.520-528, 2007. ,
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer, Blood, vol.105, pp.3051-3058, 2005. ,
Natural killer cell alloreactivity in allogeneic hematopoietic transplantation, Curr Opin Oncol, vol.19, pp.142-149, 2007. ,
NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia, J Clin Oncol, vol.28, pp.955-964, 2010. ,
,
Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience, Transfusion, vol.47, pp.520-528, 2007. ,
Glioblastoma Stem-Like Cells Are More Susceptible Than Differentiated Cells to Natural Killer Cell Lysis Mediated Through Killer Immunoglobulin-Like Receptors-Human Leukocyte Antigen Ligand Mismatch and Activation Receptor-Ligand Interactions, Int J Biochem Cell Biol, vol.9, pp.42-52, 2014. ,
Human NK cells activated by EBV lymphoblastoid cells overcome anti-apoptotic mechanisms of drug resistance in haematological cancer cells, Activated Allogeneic NK Cells Preferentially Kill Poor Prognosis B-Cell Chronic Lymphocytic Leukemia Cells. Front Immunol, vol.4, p.454, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01835574
Manufacturing Natural Killer Cells as Medicinal Products, Front Immunol, vol.7, p.504, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01438165
The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments, Front Immunol, vol.8, p.631, 2017. ,
Expanded and armed natural killer cells for cancer treatment, Cytotherapy, vol.18, pp.1422-1434, 2016. ,
Developmental and Functional Control of Natural Killer Cells by, Cytokines. Front Immunol, vol.8, p.930, 2017. ,
Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15, Blood, vol.124, pp.1081-1088, 2014. ,
Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: Clinical implications for cancer treatment, Cytotherapy, vol.18, pp.653-663, 2016. ,
Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells, Chambers AM, Lupo KB, Matosevic S. Tumor Microenvironment-Induced Immunometabolic Reprogramming of Natural Killer Cells. Front Immunol, vol.7, p.30264, 2012. ,
Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation, Semin Cancer Biol, vol.43, pp.74-89, 2017. ,
Oxidative phosphorylation induces de novo expression of the MHC class I in tumor cells through the ERK5 pathway, J Immunol, vol.185, pp.3498-503, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-02193457
MHC-I modulation due to metabolic changes regulates tumor sensitivity to CTL and NK cells, Oncoimmunology, vol.4, p.985924, 2015. ,
Effect of Natural Compounds on NK Cell Activation, J Immunol Res, p.4868417, 2018. ,
Control of Innate and Adaptive Lymphocytes by the RAR-Retinoic Acid Axis, Immune Netw, vol.18, p.1, 2018. ,
All-trans retinoic acid enhances cytotoxicity of CIK cells against human lung adenocarcinoma by upregulating MICA and IL-2 secretion, Sci Rep, vol.7, p.16481, 2017. ,
Impact of Retinoic Acid on Immune Cells and Inflammatory Diseases, Mediators Inflamm, 2018. ,
NKmediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives, Ann Transl Med, vol.7, p.105, 2019. ,
Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity, Oncoimmunology, vol.3, p.955684, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-02181343
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene, Blood, vol.99, pp.754-762, 2002. ,
A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer, J Hematol OncolJ Hematol Oncol, vol.6, p.1, 2013. ,
Obinutuzumab: what is there to learn from clinical trials?, Blood, vol.130, pp.581-589, 2017. ,
,
Armed Natural Killer Cell-Based Therapy: In Vitro and In Vivo Colorectal Peritoneal Carcinomatosis Xenograft, Mol Cancer Ther, vol.15, pp.1591-1601, 2016. ,
Natural killer cells in human autoimmune disorders, Arthritis Res Ther, vol.15, p.216, 2013. ,
High percentages and activity of synovial fluid NK cells present in patients with advanced stage active Rheumatoid Arthritis, Pathogenic Role of Immune Cells in Rheumatoid Arthritis: Implications in Clinical Treatment and Biomarker Development. Cells, vol.46, p.1351, 2002. ,
,
Natural killer type 2 bias in remission of multiple sclerosis, J Clin Invest, vol.107, pp.23-29, 2001. ,
Characterization of natural killer cells in paired CSF and blood samples during neuroinflammation, J Neuroimmunol, vol.254, pp.165-169, 2013. ,
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis, Proc Natl Acad Sci, vol.103, pp.5941-5946, 2006. ,
Tumor-Primed Human Natural Killer Cells Lyse NK-Resistant Tumor Targets: Evidence of a Two-Stage Process in Resting NK Cell Activation, J Rheumatol, vol.126, pp.605-619, 1996. ,
Cancer immunoediting: from immunosurveillance to tumor escape, Nat Immunol, vol.3, pp.991-999, 2002. ,
Dual Role of Natural Killer Cells on Graft Rejection and Control of Cytomegalovirus Infection in Renal Transplantation, Front Immunol, vol.8, p.166, 2017. ,
Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts, Blood, vol.107, pp.3624-3631, 2006. ,
IL-12-producing monocytes and HLA-E control HCMV-driven NKG2C+ NK cell expansion, J Clin Invest, vol.124, pp.5305-5316, 2014. ,
Memory-Like NK Cells: Remembering a Previous Activation by Cytokines and NK Cell Receptors, Front Immunol, vol.8, p.1143, 2017. ,
Tumor-Targeting Anti-CD20 Antibodies Mediate In Vitro Expansion of Memory Natural Killer Cells: Impact of CD16 Affinity Ligation Conditions and In Vivo Priming, Front Immunol, vol.9, 2018. ,
Natural Killer Cells for Immunotherapy -Advantages of the NK-92 Cell Line over, Blood NK Cells. Front Immunol, vol.7, 2016. ,
,
, Antileukemia activity of a natural killer cell line against human leukemias, Clin Cancer Res, vol.4, pp.2859-2868, 1998.
The human natural killer cytotoxic cell line NK-92, once armed with a murine CD16 receptor, represents a convenient cellular tool for the screening of mouse mAbs according to their ADCC potential, mAbs, vol.5, pp.587-594, 2013. ,
A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy, Oncotarget, vol.8, pp.89256-89268, 2017. ,